Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia

Leukemia and Lymphoma

Volumn 52, Issue 6, 2011, Pages 1017-1023

  Aziz, Zeba ^a   Iqbal, Javaid ^a   Aaqib, Muhammad ^a   Akram, Muhammad ^a   Saeed, Asif ^a  

^a JINNAH HOSPITAL   (Pakistan)

Author keywords

Chronic phase chronic myeloid leukemia; FACT BRM; imatinib mesylate; quality of life; tolerability

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; ARTICLE; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; COGNITIVE DEFECT; COMORBIDITY; EMOTIONAL DISORDER; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; QUESTIONNAIRE; WELLBEING;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS; YOUNG ADULT;

EID: 79957520909     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.560310     Document Type: Article

References (17)

1. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001;98:2039-2042.
2. Silver RT, Woolf SH, Hehlmann R, et al. An evidence based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia. Developed for the American Society of Hematology. Blood 1999;94:1517-1536. (Pubitemid 29411301)
3. Aziz Z, Iqbal J, Akram M, et al. Treatment of chronic myeloid leukemia in imatinib era: perspective from a developing country. Cancer 2007;109:1138-1145. (Pubitemid 46435393)
4. Homewood J, Watson M, Richards SM, et al. Treatment of CML using IFN-a: impact on quality of life. Haematol J 2003;4:253-262. (Pubitemid 36987221)
5. Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low dose cytarabine: results from the IRIS study. J Clin Oncol 2003;21:2138-2146. (Pubitemid 46606362)
6. Deininger MW, OBrien SG, Guilhot F, et al. International randomized study of interferon and STI571 (IRIS), 8 year follow-up: sustained survival and low risk of progression or events in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114(Suppl. 1): Abstract 1126.
7. Aziz Z, Iqbal J, Bano K, et al. Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country. Jpn J Clin Oncol 2010;40:549-555.
8. Malhotra P, Gupta N, Dogra SK, et al. Psychosocial profile and morbidity in Indian patients with chronic myeloid leukaemia (CML). J Clin Oncol 2008;26(Suppl.): Abstract 20753.
9. Cella DF. Manual of the functional assessment of chronic illness therapy (FACIT-scales), version 4. Evanston, IL: Center on Outcomes, Research, and Education (CORE), Evanston Northwestern Healthcare and Northwestern University; 1997.
10. Bonomi AE, Cella DF, Hahn EA, et al. Multilingual translation of the functional assessment of cancer therapy (FACT) quality of life measurement system. Qual Life Res 1996;5:309-320. (Pubitemid 26228464)
11. Mazumdar M, Bacik J, Cella DF, et al. Validation of FACTBRM (biologic response modifier) and handling of missing data in QOL analysis. Proc Soc Clin Trials 2000: p 112 [Abstract].
12. Hudgens SA, Hahn EA, Glenndenning EA, et al. Crosscultural validation of the functional assessment of cancer therapy for patients receiving biologic response modifiers (FACT-BRM). Qual Life Res 2002;11(Suppl.): Abstract 648.
13. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy (FACT) scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579. (Pubitemid 23071057)
14. Hahn EA, Cella DF. Defintion of a meaningful difference in the FACT-BRM. Evanston, IL: Center on Outcomes, Research, and Education (CORE), Evanston Northwestern Healthcare; 2002.
15. Rasch G. Probabalistic models for some intelligence and attainment tests. Copenhagen, Denmark: Pacdogogiske Institut; 1960 [Reprinted by University of Chicago Press, Chicago, IL, 1980].
16. Wright BD, Masters GN. Rating scale analysis: Rasch measurement. Chicago, IL: MESA Press; 1982.
17. Pasquini R, Clementino NC, Zanichelli MA, et al. Observational study for evaluation of quality of life in patients with chronic myeloid leukemia (CML) in use of Gleevec (imatinib mesylate). Blood 2004:104(Suppl. 1): Abstract 2932.